Medication History Review and the Availability of Breakthrough Medication in Cancer Patients Using Fentanyl Patches.
Author(s): ,
Shawn Bugden
Affiliations:
BScPharm MSc PharmD
Kevin Friesen
Affiliations:
MSc
Canadian Pharmacists Conference ePoster Library. Al-Biaty M. Jun 4, 2017; 174266
Mr. Mohamad Al-Biaty
Mr. Mohamad Al-Biaty
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

Objectives
To assess the availability and appropriateness of breakthrough pain medication in cancer patients using fentanyl patches for pain.

Methods
An observational, cohort-based study was conducted using administrative healthcare data (2001-2014) to assess pain management in a cohort of fentanyl treated cancer patients. Fentanyl doses were calculated per patient-month, and used to determine an appropriate dose of immediate release (IR) opioid for breakthrough pain. Medication history for the month of the fentanyl use, and the preceding two months was reviewed to determine if such an appropriate IR opioid had been dispensed to the patient. Each patient-month of fentanyl use was then classified according to whether an appropriate dose of IR opioid was available for treating breakthrough pain.

Results
A total of 7,910 cancer patients using transdermal fentanyl patches were identified, for a total of 47,371 patient-months of observation time. Of this, 21,138 (44.6%) patient-months were associated with no concurrent IR opioid prescriptions. A further 8,694 (18.4%) patient-months were associated with inadequate levels of concurrent IR opioids. Only 17,539 (37.0%) patient-months were found where patients had filled prescriptions that could provide adequate breakthrough pain relief if required.

Conclusion
The availability of a breakthrough IR opioid medication for cancer patients using long action opioids is considered to be a standard of care. The recent Centers for Disease Control (CDC) opioid guideline suggests that transdermal fentanyl is often misunderstood by both clinician and patients”. More than half of cancer patients treated with fentanyl patches did not receive appropriate breakthrough medications. Pharmacists, as the keeper the patients medication history, should be playing a key role in management by making recommendations to improve the quality of care provided to patients with cancer.

    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings